Author

Jane D. Robertson

Observed names: J D Robertson, J Robertson, J. D. Robertson, J. Robertson, J.D. ROBERTSON, J.D. Robertson, JD Robertson, Jane D Robertson, Jane Robertson, Robertson, J, Robertson, Jane

Institutions: The Christie Hospital, Cancer Research UK Manchester Centre

Observed institutions: AstraZeneca (United Kingdom), Radboud University Nijmegen, University of Ottawa, University of Freiburg, Flinders University, Universidade de São Paulo, University of Toronto, Queen's University, Fudan University, Juravinski Cancer Centre, Ottawa Hospital, University Medical Center Freiburg, Princess Margaret Cancer Centre, Flinders Medical Centre, Radboud University Medical Center, The Netherlands Cancer Institute, University Medical Center Utrecht, Stevenage Bioscience Catalyst, Instituto do Câncer do Estado de São Paulo, University Hospital Zurich, Royal Marsden Hospital, Cancer Research UK Manchester Institute, The Christie Hospital, Hôpital Ambroise-Paré, The Christie NHS Foundation Trust, Jena University Hospital, AstraZeneca (Sweden), Hospital Sírio-Libanês, Redx Pharma (United Kingdom), Austin Health, Cancer Research UK Manchester Centre, Canadian Cancer Trials Group, McMaster University

OpenAlex ID: A5111162935

Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors

2007 · Joachim Drevs, Patrizia Siegert, et al. · Journal of Clinical Oncology · 303

Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

2015 · Susan M. Domchek, Carol Aghajanian, et al. · Gynecologic Oncology · 298

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

2018 · Darren R. Hodgson, Brian A. Dougherty, et al. · British Journal of Cancer · 233

PDF

Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)

2012 · Hans-Joachim Schmoll, David Cunningham, et al. · Journal of Clinical Oncology · 213

Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma

2000 · J D Robertson, K Nagesh, et al. · British Journal of Cancer · 198

PDF

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety

2016 · U.A. Matulonis, R.T. Penson, et al. · Annals of Oncology · 160

PDF

Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)

2012 · Paulo M. Hoff, Andreas Hochhaus, et al. · Journal of Clinical Oncology · 155

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization

2017 · Stephanie Lheureux, Zhongwu Lai, et al. · Clinical Cancer Research · 151

PDF

Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group

2008 · Scott A. Laurie, Isabelle Gauthier, et al. · Journal of Clinical Oncology · 119

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

2017 · Brian A. Dougherty, Zhongwu Lai, et al. · Oncotarget · 97

PDF

Dynamics of telomere shortening in neutrophils and T lymphocytes during ageing and the relationship to skewed X chromosome inactivation patterns

2000 · Jane D. Robertson, Rosemary E. Gale, et al. · British Journal of Haematology · 96

Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors

2009 · Marlies H.G. Langenberg, Carla M.L. van Herpen, et al. · Journal of Clinical Oncology · 94

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy

2013 · J M Jürgensmeier, H-J Schmoll, et al. · British Journal of Cancer · 64

PDF

Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours

2010 · Hester van Cruijsen, Emile E. Voest, et al. · European Journal of Cancer · 53

Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole

2011 · Paul Martin, Stuart Oliver, et al. · Drugs in R&D · 51

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer

2013 · on behalf of the HORIZON I study group, D Cunningham, et al. · British Journal of Cancer · 49

PDF

Phase III Trial of FOLFOX plus Bevacizumab or Cediranib (AZD2171) as First-Line Treatment of Patients with Metastatic Colorectal Cancer: HORIZON III

2009 · Jane D. Robertson, Nick A. Botwood, et al. · Clinical Colorectal Cancer · 42

An open-label, Phase I study of cediranib (RECENTIN™) in patients with acute myeloid leukemia

2009 · Walter Fiedler, Rolf Mesters, et al. · Leukemia Research · 41

Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant

2001 · JD Robertson, NG Testa, et al. · Bone Marrow Transplantation · 36

Adoptive cell therapy with tumour-infiltrating lymphocytes: the emerging importance of clonal neoantigen targets for next-generation products in non-small cell lung cancer

2019 · Jane Robertson, Max Salm, et al. · Immuno-Oncology Technology · 30

PDF

Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy

2013 · S K M Spencer, A J C Pommier, et al. · British Journal of Cancer · 30

PDF

A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): Final PFS results

2008 · D. Cunningham, R. P. Wong, et al. · Journal of Clinical Oncology · 29

Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C) + paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): A study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)

2006 · S. A. Laurie, A. Arnold, et al. · Journal of Clinical Oncology · 29

Correlation of Lactate Dehydrogenase Isoenzyme Profile With Outcome in Patients With Advanced Colorectal Cancer Treated With Chemotherapy and Bevacizumab or Cediranib: Retrospective Analysis of the HORIZON I Study

2013 · Jair Bar, Stuart Spencer, et al. · Clinical Colorectal Cancer · 28

435 Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

2015 · D.R. Hodgson, B. Dougherty, et al. · European Journal of Cancer · 25

PDF

Works count: 92

Citation count: 2,835

H-index: 25

I10-index: 31